HoudaBahig Profile Banner
Houda Bahig, MD PhD Profile
Houda Bahig, MD PhD

@HoudaBahig

Followers
737
Following
3K
Media
12
Statuses
486

Radiation Oncologist & Clinician Scientist @chumontreal & @CRCHUM 🇨🇦 Views are my own

Montreal
Joined October 2017
Don't wanna be here? Send us removal request.
@HoudaBahig
Houda Bahig, MD PhD
7 days
RT @NormandBlais: Il n’y AUCUNE promesse de fournir les ressources NÉCESSAIRES dans votre projet de loi. Pas de promesse de lits d’hôpital,….
0
1
0
@HoudaBahig
Houda Bahig, MD PhD
9 days
RT @AndrearicFili: Key findings include:.1. Excellent safety and tolerability in an elderly, unfit population. 2. Median overall survival n….
0
3
0
@grok
Grok
4 days
Join millions who have switched to Grok.
176
344
3K
@HoudaBahig
Houda Bahig, MD PhD
20 days
RT @DavidSherMD: Fascinating phase III trial of nasal mupirocin to reduce oral mucositis (OM) in patients receiving radiotherapy (almost al….
0
25
0
@HoudaBahig
Houda Bahig, MD PhD
1 month
RT @drdavidpalma: Great review by @geor_li on RT in patients with early-stage NSCLC. Toxicity rates lower than in previous reviews, V5 se….
0
3
0
@HoudaBahig
Houda Bahig, MD PhD
1 month
RT @geor_li: 1/10.📢 Excited to share our new systematic review looking at risks and outcomes of definitive radiotherapy for patients with c….
0
18
0
@HoudaBahig
Houda Bahig, MD PhD
1 month
RT @JCO_ASCO: Phase III Study of Mediastinal Lymph Node Dissection for.Ground Glass Opacity–Dominant Lung Adenocarcinoma. Read the full ar….
Tweet card summary image
ascopubs.org
PURPOSESystematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate whether no mediastinal...
0
19
0
@HoudaBahig
Houda Bahig, MD PhD
1 month
RT @goodmanC_MD: Thrilled to activate PREVENT! This phase II/III RCT builds on the success of @DrAlexLouie's PROACTIVE trial by randomizing….
0
8
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @GRoussyEdu: 👨‍🎓 👩‍🎓 Il est encore temps de vous inscrire au DU Radiothérapie des #cancers ORL de @GustaveRoussy et @UnivParisSaclay. 🎓….
0
4
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @drdavidpalma: While I'm here, I'll just point out that RCTs of SABR don't show that radiation leads to more metastases. if anything th….
0
20
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @SABRCanada: #TBT to the @SABRCanada 2025 Conference on June 5-6 2025 in Kelowna, BC! . Thank you to all of our speakers and attendees f….
0
3
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @CJTsaiMDPhD: 🚨📢🌟 CURB2 Ph3 Trial is activated by @NCICTEP_ClinRes (NCT06686771), built upon CURB Ph2 RCT @TheLancet/@MSKCancerCenter.….
0
19
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @SalmaJabbour1: #elixr25 ELIXR25 early stage lung cancer conference in beautiful #Montreal & @DoctorJSpicer leading the way. Multidisc….
0
3
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @DoctorJSpicer: Thank you for all your support and contributions @HenningWillers! Was great to have you for #ELIXR25. Take note that #EL….
0
1
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @HenningWillers: #ELIXR25 Early-Stage #LungCancer Conference in beautiful #Montreal🇨🇦organized by @DoctorJSpicer @mcgillu & Team was mul….
0
8
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @CJTsaiMDPhD: 👋👋👋Final hour of #ELIXR25.Jeopardy - which team will win? Is it team 🇪🇺or 🇨🇦 or 🇺🇸?
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
4
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @HenningWillers: @DrJNaidoo discussing long term side effects of systemic therapies #ELIXR25 . Focusing on #immunotherapy side effects w….
0
5
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @CJTsaiMDPhD: ✅👍🏻Day1 of ELIXR25 - stellar lineup of speakers and panelists!. As a clinical trialist focusing on metastatic lung cancer/….
0
5
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @HenningWillers: Deep dive by @SalmaJabbour1 into the future of unresectable stage III NSCLC from biomarkers to dropping chemo.#radonc #….
0
7
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @NormandBlais: Very cruel but lively and deeply defended frenemy debate with King @FordePatrick and Queen #TinaCascone at #ELIXR25 https….
0
3
0
@HoudaBahig
Houda Bahig, MD PhD
2 months
RT @safaviaa: Systemic options are pretty limited for ACC #hncsm & toxicity risk-benefit not great, so LT (esp non-invasive SBRT #radonc) i….
0
5
0